Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Peter Clark, MA, MD, FRCP: A Payer Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




May
28
Today In Oncology
FDA Approves Durvalumab Plus BCG for High-Risk NMIBC
Local Radiotherapy May Help Control Oligometastatic Breast Cancer
TAILORx and RxPONDER Trials Shift to a Discovery Platform
Radiotherapy for Prostate Cancer: HERMES Trial Compares Two and Five Fractions
BPDCN FDA Approves Pivekimab Sunirine-pvzy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo